ArticleCancer management and research2026
Dynamic Neutrophil-to-Lymphocyte Ratio Stratifies Survival and Immune-Related Adverse Events in Lung and Gastric Cancer Patients with Immunotherapy.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dynamic neutrophil-to-lymphocyte ratio (NLR) has emerged as a prognostic marker in immunotherapy outcomes, yet phase-specific alterations in NLR after immunotherapy and their association with treatment efficacy remain underreported. This study aimed to clarify the prognostic utility of NLR dynamics in patients receiving immune checkpoint inhibitors (ICIs) therapy. Methods: We retrospectively analyzed 101 cancer patients (including lung and gastric cancer) treated with ICIs. NLR was measured at three time points: baseline (prior to ICIs initiation), Cycle 1 (C1, 1 month post-treatment), and Cycle 3 (C3, 3 months post-treatment). Pearson's chi-square test and Kaplan-Meier survival analyses were used to assess associations between NLR dynamics and immune-related adverse events (irAEs), progression-free survival (PFS), and overall survival (OS). Results: Baseline NLR showed no significance with irAEs. However, elevated C1 NLR was related with early irAEs in both lung and gastric cancers (OR = 2.883, p = 0.029). In lung cancer patients, a reduced C3 NLR was significantly associated with longer PFS (HR = 2.376, p = 0.006) and OS (HR = 3.315, p < 0.001), whereas the association was weaker in gastric cancer (PFS: HR = 1.758, p = 0.085; OS: HR = 2.284, p = 0.019). Multivariate analysis identified C3 NLR was associated independently with both PFS and OS in lung cancer patients. Furthermore, a ≥ 30% elevation in NLR stratified patients into distinct risk categories, with the potential clinical value influenced by tumor type. Conclusion: Phase-specific NLR dynamics were correlated with distinct immunotherapy outcomes. C1 NLR was associated with early toxicity in both lung and gastric cancers, whereas sustained NLR reduction at C3 was associated with more favorable survival outcomes in lung cancer. These findings suggest that longitudinal, phase-specific NLR assessment may provide complementary information for monitoring treatment-related outcomes and requires further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.